ArticleACS omega2026
GSH-Responsive Co-Delivery of Chrysin and 3‑Methyladenine Disrupts Tumor Adaptive Stress for Synergistic Antitumor Therapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, and conventional therapies are still limited by poor tumor specificity, therapeutic resistance, and systemic side effects. Herein, we developed a glutathione (GSH)-responsive FFSSFF coacervate system for the codelivery of chrysin (CH) and the autophagy inhibitor 3-methyladenine (3-MA) to induce tumor-selective autophagic stress. CH activated endoplasmic reticulum stress and promoted autophagy through the GRP78/PERK and Akt/mTOR signaling pathways, while 3-MA simultaneously disrupted autophagic flux, leading to intracellular homeostasis imbalance, mitochondrial dysfunction, excessive reactive oxygen species accumulation, and tumor cell death. The resulting CH/3-MA@FFSSFF coacervates exhibited favorable physicochemical properties, GSH-responsive behavior, efficient intracellular uptake, and selective accumulation in tumor cells. Both in vitro and in vivo experiments demonstrated potent antitumor activity of the CH/3-MA@FFSSFF system. In particular, in an orthotopic lung cancer model, CH/3-MA@FFSSFF effectively suppressed tumor growth, prolonged median survival time, and inhibited tumor cell migration and invasion. Collectively, this study presents a promising liquid-liquid phase separation-derived coacervate platform for targeted combinational cancer therapy through the induction of autophagic stress, with enhanced therapeutic efficacy and reduced off-target toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.